Associations among sleep quality, sleep duration, and Alzheimer's disease biomarkers: A systematic review and meta-analysis

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-03-27 DOI:10.1002/alz.70096

Chun-Lin Chen, Miao-Yu Zhang, Zhi-Lin Wang, Jia-Hui Deng, Yan-Ping Bao, Jie Shi, Lin Lu, Le Shi

{"title":"Associations among sleep quality, sleep duration, and Alzheimer's disease biomarkers: A systematic review and meta-analysis","authors":"Chun-Lin Chen, Miao-Yu Zhang, Zhi-Lin Wang, Jia-Hui Deng, Yan-Ping Bao, Jie Shi, Lin Lu, Le Shi","doi":"10.1002/alz.70096","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Although sleep disturbances are widely recognized as risk factors for cognitive decline and Alzheimer's disease (AD), their influence on AD biomarkers remains unclear. This study aimed to clarify whether sleep quality or sleep duration affect amyloid beta (Aβ) and tau levels in plasma, cerebrospinal fluid (CSF), and positron emission tomography (PET) in non-demented populations.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>PubMed, Web of Science, and Embase were systematically searched up to February 2025.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>In total, 30 studies were included comprising 14,997 subjects. Individuals with poor sleep quality exhibited greater PET Aβ burden and higher Aβ42 levels in plasma than those with good sleep quality. Shorter sleep duration was associated with higher Aβ burden on PET. However, no association between either sleep quality or sleep duration and tau levels was found.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Sleep may be a modifiable marker of early AD management by modulating Aβ levels.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>lPoor sleep quality and shorter sleep duration were significantly associated with higher amyloid beta (Aβ) burden detected by positron emission tomography (PET) in non-demented populations. Poor sleep quality was also associated with elevated Aβ42 levels in plasma.</li>\n \n <li>lNo significant associations were found between sleep quality or sleep duration and tau levels in plasma, cerebrospinal fluid, or PET.</li>\n \n <li>lInterventions targeting sleep could serve as a viable and low-cost prevention strategy for early management of Alzheimer's disease.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 3","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70096","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70096","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Although sleep disturbances are widely recognized as risk factors for cognitive decline and Alzheimer's disease (AD), their influence on AD biomarkers remains unclear. This study aimed to clarify whether sleep quality or sleep duration affect amyloid beta (Aβ) and tau levels in plasma, cerebrospinal fluid (CSF), and positron emission tomography (PET) in non-demented populations.

METHODS

PubMed, Web of Science, and Embase were systematically searched up to February 2025.

RESULTS

In total, 30 studies were included comprising 14,997 subjects. Individuals with poor sleep quality exhibited greater PET Aβ burden and higher Aβ42 levels in plasma than those with good sleep quality. Shorter sleep duration was associated with higher Aβ burden on PET. However, no association between either sleep quality or sleep duration and tau levels was found.

DISCUSSION

Sleep may be a modifiable marker of early AD management by modulating Aβ levels.

Highlights

lPoor sleep quality and shorter sleep duration were significantly associated with higher amyloid beta (Aβ) burden detected by positron emission tomography (PET) in non-demented populations. Poor sleep quality was also associated with elevated Aβ42 levels in plasma.
lNo significant associations were found between sleep quality or sleep duration and tau levels in plasma, cerebrospinal fluid, or PET.
lInterventions targeting sleep could serve as a viable and low-cost prevention strategy for early management of Alzheimer's disease.

Abstract Image

查看原文本刊更多论文

引言尽管睡眠障碍被广泛认为是认知能力下降和阿尔茨海默病（AD）的风险因素，但其对AD生物标志物的影响仍不明确。本研究旨在阐明睡眠质量或睡眠持续时间是否会影响非痴呆人群血浆、脑脊液（CSF）和正电子发射断层扫描（PET）中的淀粉样β（Aβ）和tau水平。方法对截至 2025 年 2 月的 PubMed、Web of Science 和 Embase 进行了系统检索。结果共纳入 30 项研究，包括 14,997 名受试者。与睡眠质量好的人相比，睡眠质量差的人 PET Aβ 负担更大，血浆中 Aβ42 水平更高。较短的睡眠时间与较高的 PET Aβ 负荷有关。然而，睡眠质量或睡眠时间与 tau 水平之间均无关联。讨论睡眠可通过调节Aβ水平成为早期AD管理的可调节标志物。亮点在非痴呆人群中，睡眠质量差和睡眠时间短与正电子发射断层扫描（PET）检测到的淀粉样β（Aβ）负荷较高明显相关。l 针对睡眠的干预措施可作为阿尔茨海默病早期管理的一种可行且低成本的预防策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.